Bavencio (Avelumab)

avelumab 200 mg/10 mL injection, 10 mL vial · INJECTION · PBS code 11671G

STREAMLINED

What it costs

AU$1289.49 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2019-05-01.
• Repeats: 11.
• PBS program: IP.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV (metastatic) Merkel Cell Carcinoma

Continuing treatment

The treatment must be the sole PBS-subsidised therapy for this condition; AND

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease progression while being treated with this drug for this condition; AND

The treatment must not exceed a maximum dose of 10 mg per kg every 2 weeks under this restriction; or

The treatment must not exceed a dose of 800 mg every 2 weeks under this restriction.

Sponsor: Merck Healthcare Pty Ltd ABN 72 006 900 830

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.